Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

Phil Hagerman, president and CEO of Diplomat Specialty Pharmacy in Flint, has been named Grant Thornton Leader & Innovator of the Year.

30 Apr 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

Pelvic MRI scan identifies local recurrence of prostate cancer at low PSA levels

A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients with a rising or persistently elevated PSA after prostatectomy, according to a study presented April 29, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

29 Apr 2011

Melatonin can help fight obesity and risks associated with it

University of Granada researchers have proven that melatonin -a natural hormone produced by the body- helps in controlling weight gain -even without reducing the intake of food-, improves blood lipid profile -as it reduces triglicerids-, increases HDL cholesterol and reduces LDL cholesterol.

29 Apr 2011

CTSN focuses on new prairie vole model for autism treatment

Researchers at the Center for Translational Social Neuroscience at Emory University are focusing on prairie voles as a new model to screen the effectiveness of drugs to treat autism.

29 Apr 2011

Study reveals dangerous chemicals in foam carpet pads

In the first public study of its kind, a type of foam carpet pad commonly sold in the USA was demonstrated to contain flame retardant chemicals that raise concerns about human health. Lowered IQ's in children exposed in utero, infertility, and cancer are among health effects linked to exposure from these halogenated chemicals.

29 Apr 2011

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

Vitamin E effective against severe fatty liver disease in some children

A specific form of vitamin E improved the most severe form of fatty liver disease in some children, according to a study funded by the National Institutes of Health. Results appear in the April 27 issue of the Journal of the American Medical Association. A previous study found vitamin E effective in some adults with the disease.

28 Apr 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

New study sheds light on sleep problems in children with autism

The current prevalence of autism spectrum disorder is alarmingly high. Although there is no cure for autism, it is possible to manage and treat the comorbid medical conditions associated with autism. One of these conditions, sleeping disturbance, can be challenging to treat.

27 Apr 2011

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Cancer researchers at hundreds of sites nationwide are about to launch a SWOG-led clinical trial that could keep thousands of breast cancer patients from getting chemotherapy that is unlikely to do them any good.

27 Apr 2011

Study finds gender difference in immune responses to PTSD

Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

27 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Scripps Research receives $1.9 million NIH grant for prostate cancer study

The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

27 Apr 2011

Newer birth control pill raises risk of blood clots

Two human trials in the US and the UK including women from both populations showed that women taking newer forms of oral contraceptives, which include drosperinone, a synthetic version of the hormone progesterone, increased their risk of developing a blood clots by two or three times over those taking older birth control pills that rely on a different form of the hormone known as levonorgestrel.

26 Apr 2011

Alkem, Karo Bio partner to license eprotirome

Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd.

26 Apr 2011

Mylan launches Letrozole Tablets for hormone receptor-positive early stage breast cancer

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Letrozole Tablets USP, 2.5 mg, under a previously announced settlement and license agreement with Novartis. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Letrozole Tablets and will market the product with a period of exclusivity.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

New book on aging

Aging is a natural part of life. From the minute we are born we are heading in one certain direction: towards death. That said, it is possible to arrive at that ultimate destination graceful and vital to our last days rather than chronically ill suffering from one or many debilitating illnesses.

25 Apr 2011

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

22 Apr 2011

Hormone News and Research

Further Reading

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Pelvic MRI scan identifies local recurrence of prostate cancer at low PSA levels

Melatonin can help fight obesity and risks associated with it

CTSN focuses on new prairie vole model for autism treatment

Study reveals dangerous chemicals in foam carpet pads

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

Vitamin E effective against severe fatty liver disease in some children

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

New study sheds light on sleep problems in children with autism

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Study finds gender difference in immune responses to PTSD

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Scripps Research receives $1.9 million NIH grant for prostate cancer study

Newer birth control pill raises risk of blood clots

Alkem, Karo Bio partner to license eprotirome

Mylan launches Letrozole Tablets for hormone receptor-positive early stage breast cancer

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

New book on aging

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News